Sandoz

Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease and ulcerative colitis

Novartis may spin off generic unit Sandoz to maximise value

"Novartis has commenced a strategic review of the Sandoz Division," the Swiss-based group said in statement alongside quarterly results in which it lifted its peak revenue estimate for its two best-selling pharmaceuticals.

Plan to enter EU market with Insulin Glargine in second half of the year: Biocon

We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.

Partnership with Sandoz is for the future wave of biosimilars: Biocon

The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.

EU regulator recommends suspending 300 drugs tested by Indian CRO firm

The European Medicines Agency (EMA) said that the suspension has been ordered for all drugs for which the bioequivalence studies were conducted by Micro Therapeutic Research Labs at two sites in India.

Starting to design clinical studies in India: Novartis

Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.

USFDA to review Biocon-Mylan's biosimilar drug for breast cancer

Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.

Cipla Q2 profit seen up 74% on export formulation biz boost

Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.

USFDA warns Novartis of violations at 2 India plants

The warning, issued to Novartis's generic drugs unit Sandoz on Oct. 22, came after FDA officials inspected its Turbhe and Kalwa sites in western India in August 2014.

Cipla rises 4% on asthma drug launch, Kotak says buy

Kotak has a buy rating on Cipla with a target price of Rs 730 per share. Expecting launch of other two strengths (USD 600 million) in days to follow , the brokerage says Cipla will receive mark-up and profit share.

CCI clears Novartis-GSK pharma deal

The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.

Ranbaxy, Sun Pharma fall 4-5%; analysts say DRL to benefit

Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.

See shared exclusivity on Copaxone generic 40mg: PLilladher

According to Surajit Pal, both Natco Pharma and Dr. Reddy‘s share exclusivity and two-three more companies are also expected to join the same.

Sandoz files citizen petition against Ranbaxy‘s Nexium FTF

CNBC-TV18's Archana Shukla reports that German pharma MNC Sandoz has filed a citizen's petition against Ranbaxy asking it to forfeit its first-to-file (FTF) status for the blockbuster drug Nexium.

Natco loses patent case against Teva of anti-sclerosis drug

Natco Pharma Ltd has lost a patent litigation against Israel's Teva Pharmaceutical Industries Ltd in the US over multiple sclerosis treatment drug, Copaxone.